Results 61 to 70 of about 162,270 (298)
mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic
Human Vaccines & Immunotherapeutics, 2022 As an acute respiratory infectious disease, COVID-19 threatens the safety of global public health. Given the current lack of specific treatment against this disease, research and development of vaccines have become sharp weapons for overcoming the ...
Peixian Chen +6 more
doaj +1 more source
Advances in saRNA Vaccine Research against Emerging/Re-Emerging Viruses
Vaccines, 2023 Although conventional vaccine approaches have proven to be successful in preventing infectious diseases in past decades, for vaccine development against emerging/re-emerging viruses, one of the main challenges is rapid response in terms of design and ...
Yalan Liu, Yuncheng Li, Qinxue Hu
doaj +1 more source
Engaging the Immune Response to Normalize the Tumor Microenvironment [PDF]
, 2013 Solid tumors exist as heterogeneous populations comprised not only of malignant cells, but various other cell types, including cells that make up the vasculature, that can strongly influence tumorgenicity.
Sabins, Nina, Storkus, Walter
core
Molecular Oncology, EarlyView.The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg +43 more
wiley +1 more source
A review of technological developments in lipid nanoparticle application for mRNA vaccination
Human Vaccines & Immunotherapeutics, 2023 Lipid nanoparticle (LNP) technology is critical to the advancement of mRNA vaccines. However, most studies focus on technical aspects and neglect the patent landscape. Moreover, there is a lack of differentiation of LNP technology differences among mRNA,
Tzu-Fu Yeh, Chen Lin, Huang-Chih Sung
doaj +1 more source
In Vitro Transcribed RNA-Based Platform Vaccines: Past, Present, and Future
Vaccines, 2023 mRNA was discovered in 1961, but it was not used as a vaccine until after three decades. Recently, the development of mRNA vaccine technology gained great impetus from the pursuit of vaccines against COVID-19.
Alexey D. Perenkov +3 more
doaj +1 more source
Translating mRNA vaccines [PDF]
Science-Business eXchange, 2012 CureVac and the Friedrich Loeffler Institute have in vivo evidence that an mRNA-based vaccine can prevent influenza A infection. The results provide proof of concept for the company's vaccine platform in infectious disease and Sanofi has options to the technology.
openaire +1 more source
Targeted modulation of IGFL2‐AS1 reveals its translational potential in cervical adenocarcinoma
Molecular Oncology, EarlyView.Cervical adenocarcinoma patients face worse outcomes than squamous cell carcinoma counterparts despite similar treatment. The identification of IGFL2‐AS1's differential expression provides a molecular basis for distinguishing these histotypes, paving the way for personalized therapies and improved survival in vulnerable populations globally.
Ricardo Cesar Cintra +6 more
wiley +1 more source
Research progress on the quality control of mRNA vaccines
Expert Review of VaccinesIntroduction The mRNA vaccine technologies have progressed rapidly in recent years. The COVID-19 pandemic has accelerated the application of mRNA vaccines, with research and development and clinical trials underway for many vaccines.
Chaoying Hu +9 more
doaj +1 more source
The advances of adjuvants in mRNA vaccines
npj Vaccines, 2023 The remarkable success of messenger RNA (mRNA) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has propelled the rapid development of this vaccination technology in recent years. Over the last three decades, numerous studies
Chunyuan Xie, Ruhui Yao, Xiaojun Xia
doaj +1 more source